Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 12After Hours

Estimated EPS

-$0.17

Estimated Rev

$0M

$ALLO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.18 up 35.71% YoY • Allogene Therapeutics expects its $266.9M in cash, cash equivalents, and investments as of March 31, 2026, plus $187.9M from the April 2026 Public Offering, will fund operations into Q1 2029.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.17
--
--
N/A
Q1 '26
-$0.19
-$0.18
5.32%
BEAT
Q4 '25
-$0.23
-$0.17
24.62%
BEAT
Q3 '25
-$0.22
-$0.19
13.95%
BEAT
Q2 '25
-$0.27
-$0.23
14.07%
BEAT

Advertisement|Remove ads.